Literature DB >> 16487169

Guidelines on the management of Waldenström macroglobulinaemia.

S A Johnson1, J Birchall, C Luckie, D G Oscier, R G Owen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16487169     DOI： 10.1111/j.1365-2141.2005.05948.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927

Review 2.  New developments in the management of Waldenström macroglobulinemia.

Authors:  Jithma P Abeykoon; Uday Yanamandra; Prashant Kapoor
Journal:  Cancer Manag Res       Date:  2017-03-10       Impact factor: 3.989

Review 3.  Rare central nervous system lymphomas.

Authors:  Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox
Journal:  Br J Haematol       Date:  2022-03-16       Impact factor: 8.615

4.  Membranoproliferative glomerulonephritis complicating Waldenström's macroglobulinemia.

Authors:  David Kratochvil; Kerstin Amann; Heike Bruck; Maike Büttner
Journal:  BMC Nephrol       Date:  2012-12-21       Impact factor: 2.388

5.  L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.

Authors:  Naoki Mori; Mari Ohwashi; Kentaro Yoshinaga; Kenjiro Mitsuhashi; Norina Tanaka; Masanao Teramura; Michiko Okada; Masayuki Shiseki; Junji Tanaka; Toshiko Motoji
Journal:  PLoS One       Date:  2013-11-05       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.